Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Europe Bronchiectasis Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991796
Published Content info 392 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe Bronchiectasis Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 392 Pages
Description

Europe bronchiectasis market is projected to register a CAGR of 5.6% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

Europe Bronchiectasis Market, By Disease Type (CF Bronchiectasis and Non-CF Bronchiectasis), Severity (Mild to Moderate and Moderate-to-Severe), Type (Diagnosis and Treatment), Drugs Type (Branded and Generics), Route of Administration (Oral, Parenteral and Inhalation), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe) Industry Trends and Forecast to 2028.

Some of the major factors contributing to the growth of Europe bronchiectasis market are:

  • Technological advancement for disease testing
  • Rising awareness for prevention of bronchiectasis in primary and secondary care

Market Players:

The key market players for Europe bronchiectasis market are listed below:

  • Abbott
  • HERSILL
  • Indogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Medline Industries, Inc.
  • Ache Laboratories Farmaceuticos S.A.
  • Horizon Therapeutics plc
  • Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)
  • Trudell Medical International
  • GlaxoSmithKline plc
  • AstraZeneca
  • Pfizer Inc.
  • Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.)
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.)
  • Viatris Inc.
  • Covis Pharma
  • Cipla Inc.
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF EUROPE BRONCHIECTASIS MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 DISEASE TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 MARKET DRUGS TYPE COVERAGE GRID
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

5 EUROPE BRONCHIECTASIS MARKET: LAWS AND REGULATIONS

6 EPIDEMIOLOGY

7 MARKET OVERVIEW

  • 7.1 DRIVERS
    • 7.1.1 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS
    • 7.1.2 GROWING GERIATRIC POPULATION
    • 7.1.3 RISING NUMBER OF SMOKERS AND CONSUMPTION OF ALCOHOL
    • 7.1.4 TECHNOLOGICAL ADVANCEMENT FOR DISEASE TESTING
    • 7.1.5 GROWING DIAGNOSTIC RATE
  • 7.2 RESTRAINTS
    • 7.2.1 HIGH COST OF DIAGNOSTIC TOOLS
    • 7.2.2 PRODUCT RECALLS
    • 7.2.3 INAPPROPRIATE REIMBURSEMENT POLICIES
  • 7.3 OPPORTUNITIES
    • 7.3.1 RISING AWARENESS FOR PREVENTION OF BRONCHIECTASIS IN PRIMARY AND SECONDARY CARE
    • 7.3.2 INCREASING HEALTHCARE EXPENDITURE
    • 7.3.3 INCREASE IN RESEARCH REGARDING THE BRONCHIECTASIS DISEASE
    • 7.3.4 AVAILABILITY OF GENERIC DRUGS IN UNDERDEVELOPED AND DEVELOPING COUNTRIES
  • 7.4 CHALLENGES
    • 7.4.1 COMPLICATIONS IN THE TREATMENT OF BRONCHIECTASIS
    • 7.4.2 LACK OF SKILLED PROFESSIONALS
    • 7.4.3 DIAGNOSITIC CHALLENGES

8 IMPACT OF COVID-19

  • 8.1 PRICE IMPACT
  • 8.2 IMPACT ON DEMAND
  • 8.3 IMPACT ON SUPPLY CHAIN
  • 8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
  • 8.5 CONCLUSION

9 EUROPE BRONCHIECTASIS MARKET, BY DISEASE TYPE

  • 9.1 OVERVIEW
  • 9.2 NON-CF BRONCHIECTASIS
  • 9.3 CF BRONCHIECTASIS

10 EUROPE BRONCHIECTASIS MARKET, BY SEVERITY

  • 10.1 OVERVIEW
  • 10.2 MILD TO MODERATE
  • 10.3 MODERATE TO SEVERE

11 EUROPE BRONCHIECTASIS MARKET, BY TYPE

  • 11.1 OVERVIEW
  • 11.2 TREATMENT
    • 11.2.1 ANTIBIOTICS
      • 11.2.1.1 MACROLIDE
        • 11.2.1.1.1 AZITHROMYCIN
        • 11.2.1.1.2 CLARITHROMYCIN
        • 11.2.1.1.3 OTHERS
      • 11.2.1.2 AMOXICILLIN
      • 11.2.1.3 CEPHALOSPORIN
        • 11.2.1.3.1 SECOND-GENERATION CEPHALOSPORIN
        • 11.2.1.3.2 THIRD-GENERATION CEPHALOSPORIN
      • 11.2.1.4 AMINOGLYCOSIDE
        • 11.2.1.4.1 GENTAMICIN
        • 11.2.1.4.2 TOBRAMYCIN
      • 11.2.1.5 FLUOROQUINOLONE
      • 11.2.1.6 TETRACYCLINS
      • 11.2.1.7 TRIMETHOPRIM-SULFAMETHOXAZOLE
      • 11.2.1.8 COMBINATION THERAPY
    • 11.2.2 CORTICOSTEROIDS
      • 11.2.2.1 BUDESONIDE
      • 11.2.2.2 FLUTICASONE
      • 11.2.2.3 MOMETASONE
      • 11.2.2.4 FLUNISOLIDE
      • 11.2.2.5 OTHERS
    • 11.2.3 BRONCHODILATORS
      • 11.2.3.1 LONG-ACTING BRONCHODILATORS
        • 11.2.3.1.1 FORMOTEROL
        • 11.2.3.1.2 TIOTROPIUM
        • 11.2.3.1.3 SALMETEROL
        • 11.2.3.1.4 OTHERS
      • 11.2.3.2 SHORT-ACTING BRONCHODILATORS
        • 11.2.3.2.1 ALBUTEROL
        • 11.2.3.2.2 LEVALBUTEROL
        • 11.2.3.2.3 OTHERS
    • 11.2.4 MUCUS THINNING MEDICINE
      • 11.2.4.1 CARBOCISTEINE
      • 11.2.4.2 BROMHEXINE
      • 11.2.4.3 OTHERS
    • 11.2.5 AIRWAY CLEARANCE DEVICES
      • 11.2.5.1 OSCILLATING POSITIVE EXPIRATORY PRESSURE (PEP)
      • 11.2.5.2 INTRAPULMONARY PERCUSSIVE VENTILATION (IPV)
      • 11.2.5.3 POSTURAL DRAINAGE
      • 11.2.5.4 OTHERS
    • 11.2.6 OXYGEN THERAPY
      • 11.2.6.1 OXYGEN CONCENTRATORS
      • 11.2.6.2 COMPRESSED GAS OXYGEN
      • 11.2.6.3 LIQUID OXYGEN
    • 11.2.7 SURGERY
      • 11.2.7.1 BRONCHOSCOPY
      • 11.2.7.2 LUNG TRANSPLANT
    • 11.2.8 OTHERS
  • 11.3 DIAGNOSIS
    • 11.3.1 CHEST CT SCAN
    • 11.3.2 SPUTUM TEST
    • 11.3.3 PULMONARY FUNCTION TEST
    • 11.3.4 X-RAY
    • 11.3.5 OTHERS

12 EUROPE BRONCHIECTASIS MARKET, BY DRUGS TYPE

  • 12.1 OVERVIEW
  • 12.2 BRANDED
  • 12.3 GENERICS

13 EUROPE BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION

  • 13.1 OVERVIEW
  • 13.2 INHALATION
  • 13.3 ORAL
    • 13.3.1 TABLETS
    • 13.3.2 CAPSULES
    • 13.3.3 OTHERS
  • 13.4 PARENTERAL
    • 13.4.1 INTRAVENOUS
    • 13.4.2 SUBCUTANEOUS
    • 13.4.3 OTHERS

14 EUROPE BRONCHIECTASIS MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 CLINICS
  • 14.4 HOME HEALTHCARE
  • 14.5 OTHERS

15 EUROPE BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 HOSPITAL PHARMACY
  • 15.3 RETAIL PHARMACY
  • 15.4 ONLINE PHARMACY
  • 15.5 OTHERS

16 EUROPE BRONCHIECTASIS MARKET BY GEOGRAPHY

  • 16.1 OVERVIEW
  • 16.2 EUROPE
    • 16.2.1 GERMANY
    • 16.2.2 FRANCE
    • 16.2.3 U.K.
    • 16.2.4 ITALY
    • 16.2.5 SPAIN
    • 16.2.6 NETHERLANDS
    • 16.2.7 RUSSIA
    • 16.2.8 SWITZERLAND
    • 16.2.9 BELGIUM
    • 16.2.10 TURKEY
    • 16.2.11 AUSTRIA
    • 16.2.12 NORWAY
    • 16.2.13 HUNGARY
    • 16.2.14 LITHUANIA
    • 16.2.15 IRELAND
    • 16.2.16 POLAND
    • 16.2.17 REST OF EUROPE

17 EUROPE BRONCHIECTASIS MARKET: COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: EUROPE

18 SWOT

19 COMPANY PROFILES

  • 19.1 ASTRAZENECA
    • 19.1.1 COMPANY SNAPSHOT
    • 19.1.2 REVENUE ANALYSIS
    • 19.1.3 COMPANY SHARE ANALYSIS
    • 19.1.4 PRODUCT PORTFOLIO
    • 19.1.5 RECENT DEVELOPMENTS
  • 19.2 GLAXOSMITHKLINE PLC.
    • 19.2.1 COMPANY SNAPSHOT
    • 19.2.2 REVENUE ANALYSIS
    • 19.2.3 COMPANY SHARE ANALYSIS
    • 19.2.4 PRODUCT PORTFOLIO
    • 19.2.5 RECENT DEVELOPMENTS
  • 19.3 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
    • 19.3.1 COMPANY SNAPSHOT
    • 19.3.2 REVENUE ANALYSIS
    • 19.3.3 COMPANY SHARE ANALYSIS
    • 19.3.4 PRODUCT PORTFOLIO
    • 19.3.5 RECENT DEVELOPMENTS
  • 19.4 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
    • 19.4.1 COMPANY SNAPSHOT
    • 19.4.2 REVENUE ANALYSIS
    • 19.4.3 COMPANY SHARE ANALYSIS
    • 19.4.4 PRODUCT PORTFOLIO
    • 19.4.5 RECENT DEVELOPMENTS
  • 19.5 NOVARTIS AG
    • 19.5.1 COMPANY SNAPSHOT
    • 19.5.2 REVENUE ANALYSIS
    • 19.5.3 PRODUCT PORTFOLIO
    • 19.5.4 RECENT DEVELOPMENTS
  • 19.6 ABBOTT
    • 19.6.1 COMPANY SNAPSHOT
    • 19.6.2 REVENUE ANALYSIS
    • 19.6.3 PRODUCT PORTFOLIO
    • 19.6.4 RECENT DEVELOPMENT
  • 19.7 ACHE LABORATORIES FARMACEUTICOS S.A.
    • 19.7.1 COMPANY SNAPSHOT
    • 19.7.2 PRODUCT PORTFOLIO
    • 19.7.3 RECENT DEVELOPMENTS
  • 19.8 BAYER AG
    • 19.8.1 COMPANY SNAPSHOT
    • 19.8.2 REVENUE ANALYSIS
    • 19.8.3 PRODUCT PORTFOLIO
    • 19.8.4 RECENT DEVELOPMENTS
  • 19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 19.9.1 COMPANY SNAPSHOT
    • 19.9.2 REVENUE ANALYSIS
    • 19.9.3 PRODUCT PORTFOLIO
    • 19.9.4 RECENT DEVELOPMENT
  • 19.10 CIPLA INC.
    • 19.10.1 COMPANY SNAPSHOT
    • 19.10.2 REVENUE ANALYSIS
    • 19.10.3 PRODUCT PORTFOLIO
    • 19.10.4 RECENT DEVELOPMENTS
  • 19.11 COVIS PHARMA
    • 19.11.1 COMPANY SNAPSHOT
    • 19.11.2 PRODUCT PORTFOLIO
    • 19.11.3 RECENT DEVELOPMENT
  • 19.12 DR. REDDY'S LABORATORIES LTD.
    • 19.12.1 COMPANY SNAPSHOT
    • 19.12.2 REVENUE ANALYSIS
    • 19.12.3 PRODUCT PORTFOLIO
    • 19.12.4 RECENT DEVELOPMENTS
  • 19.13 ELECTROMED, INC.
    • 19.13.1 COMPANY SNAPSHOT
    • 19.13.2 REVENUE ANALYSIS
    • 19.13.3 PRODUCT PORTFOLIO
    • 19.13.4 RECENT DEVELOPMENTS
  • 19.14 HERSILL
    • 19.14.1 COMPANY SNAPSHOT
    • 19.14.2 PRODUCT PORTFOLIO
    • 19.14.3 RECENT DEVELOPMENTS
  • 19.15 HOME OXYGEN COMPANY
    • 19.15.1 COMPANY SNAPSHOT
    • 19.15.2 PRODUCT PORTFOLIO
    • 19.15.3 RECENT DEVELOPMENT
  • 19.16 HORIZON THERAPEUTICS PLC
    • 19.16.1 COMPANY SNAPSHOT
    • 19.16.2 REVENUE ANALYSIS
    • 19.16.3 PRODUCT PORTFOLIO
    • 19.16.4 RECENT DEVELOPMENT
  • 19.17 INOGEN, INC.
    • 19.17.1 COMPANY SNAPSHOT
    • 19.17.2 REVENUE ANALYSIS
    • 19.17.3 PRODUCT PORTFOLIO
    • 19.17.4 RECENT DEVELOPMENTS
  • 19.18 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
    • 19.18.1 COMPANY SNAPSHOT
    • 19.18.2 REVENUE ANALYSIS
    • 19.18.3 PRODUCT PORTFOLIO
    • 19.18.4 RECENT DEVELOPMENT
  • 19.19 MEDLINE INDUSTRIES, INC.
    • 19.19.1 COMPANY SNAPSHOT
    • 19.19.2 PRODUCT PORTFOLIO
    • 19.19.3 RECENT DEVELOPMENTS
  • 19.20 PFIZER INC.
    • 19.20.1 COMPANY SNAPSHOT
    • 19.20.2 REVENUE ANALYSIS
    • 19.20.3 PRODUCT PORTFOLIO
    • 19.20.4 RECENT DEVELOPMENTS
  • 19.21 SUNOVION PHARMACEUTICALS INC. (A SUBSIDIARY OF SUMITOMO DAINIPPON PHARMA CO., LTD.)
    • 19.21.1 COMPANY SNAPSHOT
    • 19.21.2 REVENUE ANALYSIS
    • 19.21.3 PRODUCT PORTFOLIO
    • 19.21.4 RECENT DEVELOPMENTS
  • 19.22 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 19.22.1 COMPANY SNAPSHOT
    • 19.22.2 REVENUE ANALYSIS
    • 19.22.3 PRODUCT PORTFOLIO
    • 19.22.4 RECENT DEVELOPMENTS
  • 19.23 TRUEDELL MEDICAL INTERNATIONAL
    • 19.23.1 COMPANY SNAPSHOT
    • 19.23.2 PRODUCT PORTFOLIO
    • 19.23.3 RECENT DEVELOPMENTS
  • 19.24 VIATRIS INC.
    • 19.24.1 COMPANY SNAPSHOT
    • 19.24.2 PRODUCT PORTFOLIO
    • 19.24.3 RECENT DEVELOPMENTS
  • 19.25 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
    • 19.25.1 COMPANY SNAPSHOT
    • 19.25.2 REVENUE ANALYSIS
    • 19.25.3 PRODUCT PORTFOLIO
    • 19.25.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

LIST OF FIGURES

  • FIGURE 1 EUROPE BRONCHIECTASIS MARKET: SEGMENTATION 57
  • FIGURE 2 EUROPE BRONCHIECTASIS MARKET : DATA TRIANGULATION 60
  • FIGURE 3 EUROPE BRONCHIECTASIS MARKET: DROC ANALYSIS 61
  • FIGURE 4 EUROPE BRONCHIECTASIS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 62
  • FIGURE 5 EUROPE BRONCHIECTASIS MARKET: COMPANY RESEARCH ANALYSIS 62
  • FIGURE 6 EUROPE BRONCHIECTASIS MARKET: MULTIVARIATE MODELLING 63
  • FIGURE 7 EUROPE BRONCHIECTASIS MARKET: INTERVIEW DEMOGRAPHICS 64
  • FIGURE 8 EUROPE BRONCHIECTASIS MARKET: DBMR MARKET POSITION GRID 65
  • FIGURE 9 EUROPE BRONCHIECTASIS MARKET: VENDOR SHARE ANALYSIS 66
  • FIGURE 10 EUROPE BRONCHIECTASIS MARKET: MARKET DRUGS TYPE COVERAGE GRID 67
  • FIGURE 11 EUROPE BRONCHIECTASIS MARKET: SEGMENTATION 71
  • FIGURE 12 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS IS DRIVING THE EUROPE BRONCHIECTASIS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 72
  • FIGURE 13 NON-CF BRONCHIECTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BRONCHIECTASIS MARKET IN 2021 & 2028 72
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE BRONCHIECTASIS MARKET 82
  • FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050 84
  • FIGURE 16 PREVALENCE OF BRONCHIECTASIS BY AGE IN KOREA POPULATION (2019) 84
  • FIGURE 17 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS 90
  • FIGURE 18 EUROPE BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2021 98
  • FIGURE 19 EUROPE BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION) 99
  • FIGURE 20 EUROPE BRONCHIECTASIS MARKET: BY DISEASE TYPE, CAGR (2021-2028) 99
  • FIGURE 21 EUROPE BRONCHIECTASIS MARKET: BY DISEASE TYPE, LIFELINE CURVE 100
  • FIGURE 22 EUROPE BRONCHIECTASIS MARKET: BY SEVERITY, 2021 104
  • FIGURE 23 EUROPE BRONCHIECTASIS MARKET: BY SEVERITY, 2019-2028 (USD MILLION) 105
  • FIGURE 24 EUROPE BRONCHIECTASIS MARKET: BY SEVERITY, CAGR(2021-2028) 105
  • FIGURE 25 EUROPE BRONCHIECTASIS MARKET: BY SEVERITY, LIFELINE CURVE 106
  • FIGURE 26 EUROPE BRONCHIECTASIS MARKET: BY TYPE, 2021 110
  • FIGURE 27 EUROPE BRONCHIECTASIS MARKET: BY TYPE, 2019-2028 (USD MILLION) 111
  • FIGURE 28 EUROPE BRONCHIECTASIS MARKET: BY TYPE, CAGR (2021-2028) 111
  • FIGURE 29 EUROPE BRONCHIECTASIS MARKET: BY TYPE, LIFELINE CURVE 112
  • FIGURE 30 EUROPE BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2021 126
  • FIGURE 31 EUROPE BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2019-2028 (USD MILLION) 127
  • FIGURE 32 EUROPE BRONCHIECTASIS MARKET: BY DRUGS TYPE, CAGR (2021-2028) 127
  • FIGURE 33 EUROPE BRONCHIECTASIS MARKET: BY DRUGS TYPE, LIFELINE CURVE 128
  • FIGURE 34 EUROPE BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2021 132
  • FIGURE 35 EUROPE BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 133
  • FIGURE 36 EUROPE BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028) 133
  • FIGURE 37 EUROPE BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 134
  • FIGURE 38 EUROPE BRONCHIECTASIS MARKET: BY END USER, 2021 140
  • FIGURE 39 EUROPE BRONCHIECTASIS MARKET: BY END USER, 2019-2028 (USD MILLION) 141
  • FIGURE 40 EUROPE BRONCHIECTASIS MARKET: BY END USER, CAGR (2021-2028) 141
  • FIGURE 41 EUROPE BRONCHIECTASIS MARKET: BY END USER, LIFELINE CURVE 142
  • FIGURE 42 EUROPE BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2021 147
  • FIGURE 43 EUROPE BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 148
  • FIGURE 44 EUROPE BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028) 148
  • FIGURE 45 EUROPE BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 149
  • FIGURE 46 EUROPE BRONCHIECTASIS MARKET: SNAPSHOT (2020) 154
  • FIGURE 47 EUROPE BRONCHIECTASIS MARKET: BY COUNTRY (2020) 156
  • FIGURE 48 EUROPE BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 156
  • FIGURE 49 EUROPE BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 157
  • FIGURE 50 EUROPE BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 157
  • FIGURE 51 EUROPE BRONCHIECTASIS MARKET: SNAPSHOT (2020) 159
  • FIGURE 52 EUROPE BRONCHIECTASIS MARKET: BY COUNTRY (2020) 161
  • FIGURE 53 EUROPE BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 161
  • FIGURE 54 EUROPE BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 162
  • FIGURE 55 EUROPE BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 162
  • FIGURE 56 EUROPE BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%) 283
Back to Top